Roth Capital Upgrades Trinity Biotech (TRIB) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TRIB Hot Sheet
Price: $6.43 -1.98%
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Roth Capital upgraded Trinity Biotech (NASDAQ: TRIB) from Neutral to Buy with a price target of $30.00.
For an analyst ratings summary and ratings history on Trinity Biotecjh click here. For more ratings news on Trinity Biotecjh click here.
Shares of Trinity Biotecjh closed at $24.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform
- Craig-Hallum Upgrades Navitas Semiconductor (NVTS) to Buy
- JPMorgan Upgrades Koito Manufacturing Co Ltd. (7276:JP) (KOTMF) to Overweight
Create E-mail Alert Related Categories
UpgradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
